



I hereby certify that the correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria VA 22313-1450, on the date shown below.

Dated: December 29, 2004


Katherine L. Neville

Docket No.: 27866/37524

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gallatin et al

Application No.: 09/891,943

Group Art Unit: 1644

Filed: June 26, 2001

Examiner: P. Gambel

For: Novel Human Beta-2 Integrin Alpha Subunit

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

This paper is in response to an outstanding Office Action (hereinafter, the "Action"), mailed June 29, 2004, in the above-mentioned application. In the Action, the examiner maintains the rejection of claims 11, 12 and 14 under 35 U.S.C. § 112, first paragraph, for asserted lack of enablement. Claim 14 is further rejected under 35 U.S.C. § 112, second paragraph for asserted indefiniteness. The Examiner also rejected claims 11, 12 and 14 under 35 U.S.C. 102 (b) as allegedly being anticipated by Gallatin *et al.*, US Patent No. 5,437,958 (hereinafter "Gallatin").

Amendments to the Claims are reflected in the listing of claims which begin on page 2 of this paper.

Amendments to the Specification are found on page 4 of this paper

Remarks begin on page 5 of this paper.

01/27/2005 6DUCKETT 00000007 132855
01 FC:1203 360.00 DA